加减半夏泻心汤治疗幽门螺杆菌相关性慢性胃炎(脾胃湿热证)的Meta分析OA

Objective:To systematically evaluate the clinical efficacy of modified Banxia Xiexin decoction(半夏泻心汤)in the treatment of Helicobacter pylori(Hp)-related chronic gastritis(spleen-stomach damp-heat syndrome).Methods:From the PubMed,Cochrane Library,CBM,WOS,VIP,CNKI,and Wanfang Database,the RCTs published from the establishment of each database until April 28,2025,for the treatment of Hp-related chronic gastritis(spleen-stomach damp-heat syndrome)with Modified Banxia Xiexin decoction were retrieved.After inclusion and exclusion of relevant literature,basic information and various indicator data were extracted from the finally included studies.RevMan 5.4 and Stata 18 software were used to assess the risk of bias and conduct data analysis of the finally included literature.Results:A total of 14 studies involving 1 111 patients were included.The meta-analysis showed that the experimental group(Modified Banxia Xiexin decoction group)was superior to the control group,as it significantly reduced the scores of each traditional Chinese medicine(TCM)syndrome symptom:epigastric pain[SMD=-2.78,95%CI(-3.94,-1.62),P<0.000 01],epigastric fullness[SMD=-2.17,95%CI(-2.45,-1.90),P<0.000 01],epigastric burning[SMD=-8.90,95%CI(-9.95,-7.84),P<0.000 01],nausea and vomiting[SMD=-2.23,95%CI(-2.58,-1.89),P<0.000 01],and halitosis[SMD=-2.50,95%CI(-2.83,-2.17),P<0.000 01].Additionally,it improved the overall clinical response rate[RR=1.23,95%CI(1.16,1.29),P<0.000 01],increased the Hp eradication rate[RR=1.25,95%CI(1.18,1.32),P<0.000 01],and reduced the incidence of adverse reactions[RR=0.31,95%CI(0.10,0.93),P<0.05].Conclusion:Compared to conventional Western medicine treatment alone in the control group,modified Banxia Xiexin decoction combined with the control group's medication regimen can improve the efficacy rate in treating Hp-related chronic gastritis(spleen-stomach damp-heat syndrome),alleviate clinical symptoms such as epigastric pain,epigastric fullness,epigastric burning,nausea and vomiting,and halitosis,enhance the Hp eradication rate,and reduce adverse reactions.However,further validation and support from larger-scale,multicenter,and high-quality randomized controlled trials are needed in the future.